Global law firm Willkie Farr Gallagher has named Kirk A. Radke as a partner in its private equity practice group. The appointment becomes effective February 3, 2014.
We are pleased to announce that Kirk A. Radke has joined the firm’s Private Equity Practice Group as a partner in New York, effective February 3, 2014.
Kirk, recognized as a leading private equity practitioner, comes to Willkie with an international reputation for his private equity expertise, dealmaking experience, industry knowledge and relationships. Kirk has an extensive and well-known track record representing numerous private equity sponsors and their portfolio companies.
“Kirk is recognized internationally as a thought leader in the field. Kirk’s joining Willkie further strengthens our private equity platform, which we believe is now recognized by clients and practitioners as one of the very best in the United States and Europe. The addition of Kirk highlights our ongoing commitment to providing the highest level of excellence for our clients,” said Steven Gartner, Co-Chairman of the firm.
“The increasingly complex and sophisticated nature of the private equity environment requires an integrated and focused approach in order to help clients gain a competitive advantage. Willkie’s deep experience, market credibility, and integrated approach to private equity deal making, regulation and fund formation provides that advantage. I am pleased to be joining a group of entrepreneurial-minded colleagues and a firm that is highly regarded in the private equity business globally,” said Mr. Radke.
The addition of Kirk caps off a stellar year for our private equity practice. Select leveraged buyouts and private equity transactions handled by Willkie include representing Hudson’s Bay Company in its $2.9 billion leveraged cross-border acquisition of Saks Incorporated; Insight Venture Partners in the closing of Insight’s recent $2.57 billion private equity fund; Pearl Therapeutics in its $1.15 billion sale to AstraZeneca; Rockwood Holdings, Inc. in its $1.98 billion sale of CeramTec to Cinven; Brookfield Property Partners in its $1.4 billion investment in GGP; Warburg Pincus in the closing of its recent $11.2 billion global fund, and in its recent $490 million sale of JHP Pharmaceuticals.